Login
Products
Login
Home
Alerts
Search
Watchlist
Products

Kaya Ltd

KAYA
NSE
259.95
1.17%
Last Updated:
30 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

Kaya Ltd

KAYA
NSE
259.95
1.17%
30 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
395Cr
Close
Close Price
259.95
Industry
Industry
Miscellaneous
PE
Price To Earnings
PS
Price To Sales
1.78
Revenue
Revenue
221Cr
Rev Gr TTM
Revenue Growth TTM
3.29%
PAT Gr TTM
PAT Growth TTM
785.33%
Peer Comparison
How does KAYA stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
KAYA
VS

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
936051545252535855535460
Growth YoY
Revenue Growth YoY%
10.9-35.7-44.5-45.6-44.0-13.13.66.85.51.82.53.3
Expenses
ExpensesCr
11753414411746475353495771
Operating Profit
Operating ProfitCr
-2561011-6566524-3-11
OPM
OPM%
-26.710.518.819.5-126.111.110.88.23.17.0-6.2-19.1
Other Income
Other IncomeCr
111121111414-4
Interest Expense
Interest ExpenseCr
1766777888899
Depreciation
DepreciationCr
161099999109101112
PBT
PBTCr
-56-9-4-4-790-11-11-11-14-19-36
Tax
TaxCr
000000000000
PAT
PATCr
-56-10-12-9-99103-164-7-14-19-36
Growth YoY
PAT Growth YoY%
-36.359.529.549.6-76.01,089.4-34.6141.192.9-113.7-19.7-1,066.3
NPM
NPM%
-60.9-17.4-23.0-16.5-191.5198.1-29.86.3-12.8-26.7-34.8-59.2
EPS
EPS
-43.1-7.9-8.9-6.9-75.978.6-12.02.8-5.4-10.8-13.2-23.4

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
332370410400421393275324377205217221
Growth
Revenue Growth%
11.310.9-2.45.1-6.6-30.117.816.3-45.55.81.9
Expenses
ExpensesCr
300357400403412343252310401242199231
Operating Profit
Operating ProfitCr
331310-38502314-24-3718-9
OPM
OPM%
9.83.62.5-0.82.012.88.34.3-6.5-18.18.2-4.2
Other Income
Other IncomeCr
111210929151255176
Interest Expense
Interest ExpenseCr
0001317151636263134
Depreciation
DepreciationCr
121720242975607861353842
PBT
PBTCr
3290-20-21-33-37-68-116-94-33-80
Tax
TaxCr
0000-621000000
PAT
PATCr
3290-20-16-54-37-68-116-94-33-75
Growth
PAT Growth%
-72.1-102.0-11,203.121.2-247.430.9-81.7-71.119.464.4-126.1
NPM
NPM%
9.62.40.0-4.9-3.7-13.8-13.6-21.0-30.9-45.7-15.4-34.1
EPS
EPS
24.66.8-21.7-15.2-12.2-41.7-29.1-52.7-89.2-98.964.0-52.7

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
01313131313131313131315
Reserves
ReservesCr
2222382381971456941-15-117-240-153-108
Current Liabilities
Current LiabilitiesCr
129142143137180189182196249286142145
Non Current Liabilities
Non Current LiabilitiesCr
913312329138131166224236234255
Total Liabilities
Total LiabilitiesCr
373407426372368409368361370295237308
Current Assets
Current AssetsCr
232231185120115957810614310266111
Non Current Assets
Non Current AssetsCr
141176240252254314290255227194171197
Total Assets
Total AssetsCr
373407426372368409368361370295237308

Cash Flow

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
325-6-122247323063391
Investing Cash Flow
Investing Cash FlowCr
-17-6-4124-28-124-35-40-925
Financing Cash Flow
Financing Cash FlowCr
0033-75-47-3112-18-38-37
Net Cash Flow
Net Cash FlowCr
160-135-1-11585-7-11
Free Cash Flow
Free Cash FlowCr
-4-37-31-45-12382915395-21
CFO To PAT
CFO To PAT%
101.554.23,412.858.3-139.6-87.3-84.5-44.0-54.0-41.4-3.6
CFO To EBITDA
CFO To EBITDA%
98.535.9-59.1375.4257.093.9139.0217.2-258.1-104.36.8

Ratios

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
01,1101,0141,361935146387458331410306
Price To Earnings
Price To Earnings
0.0126.30.00.00.00.00.00.00.00.03.6
Price To Sales
Price To Sales
0.03.02.53.42.20.41.41.40.92.01.4
Price To Book
Price To Book
0.04.44.46.55.91.87.1-294.4-3.2-1.8-2.2
EV To EBITDA
EV To EBITDA
-0.980.9100.8-441.1110.55.923.246.2-21.6-18.631.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
91.289.489.596.696.295.696.196.796.593.293.0
OPM
OPM%
9.83.62.5-0.82.012.88.34.3-6.5-18.18.2
NPM
NPM%
9.62.40.0-4.9-3.7-13.8-13.6-21.0-30.9-45.7-15.4
ROCE
ROCE%
14.33.50.1-8.3-10.3-6.8-10.9-25.9-55.5-90.8-2.3
ROE
ROE%
14.33.5-0.1-9.4-9.9-66.3-68.74,372.9112.141.323.9
ROA
ROA%
8.52.20.0-5.3-4.2-13.2-10.2-18.8-31.4-31.7-14.1
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
#### **Overview** Kaya Limited is India’s leading dermatology-led aesthetic healthcare provider, with a strong two-decade legacy since its founding in 2003 by Harsh Mariwala. Operating under a unique model that blends **medical expertise, retail innovation, and hospitality-driven customer experience**, Kaya has established itself as a category-defining brand in the organized aesthetic dermatology sector. The company serves **over 3 million clients** across India through a nationwide network of **82 clinics**, staffed by **over 100 dermatologists** and supported by a team of trained beauty professionals. Kaya offers **600+ clinical service lines** and markets **75+ dermatologist-developed skincare, haircare, body care, and nutraceutical products** under the “Dermat Curated” philosophy. Following a strategic refocus in 2024, Kaya has exited its Middle East operations (GCC entities), divesting Kaya DMCC and FZE to **Humania GCC Holding Limited**, to concentrate exclusively on accelerating growth in the high-potential Indian market. --- #### **Core Business Segments** Kaya’s business model is built around three integrated pillars: 1. **Clinical Services (86% of revenue in FY25):** Delivering science-backed, dermatologist-guided treatments for skin, hair, and body concerns. 2. **Retail Products (14% of revenue in FY25):** Featuring in-house R&D-developed formulations sold via clinics, e-commerce, and FMCG partnerships. 3. **Digital & Technology Platforms:** Driving personalization, access, and engagement through AI, automation, and omnichannel integration. --- #### **Key Service Offerings** Kaya’s clinical portfolio targets high-demand aesthetic segments with medical precision: - **Laser Hair Reduction (LHR):** A **key customer acquisition driver**, especially among men and women seeking long-term, non-invasive solutions. Uses FDA-approved **Alma Soprano Titanium** technology. - **Anti-Ageing:** Comprehensive treatments including **Botox, fillers, HIFU, Profhilo, Dermafrac, Thermage FLX**, and chemical peels. - **Pigmentation & Brightening:** Advanced, low-downtime therapies using **Q-Switch lasers, tailored chemical peels**, and post-care regimens. - **Hair Regeneration:** Root-cause focused solutions like **PRP, GFC-PRP, Derma Roller, Nutri Infusions, and Regenera**, supported by scalp diagnostics. - **Body Contouring & Sculpting:** In-demand services using **CoolSculpting, CM Slim, Venus Legacy, cryolipolysis, radiofrequency lipolysis**, and muscle stimulation technologies. Projected to grow at **14.9% CAGR (FY25–FY29)**. - **Wellness & Inner Beauty:** **IV drip infusions (glutathione, vitamins), nutraceuticals (collagen peptides, hair & skin supplements)**. --- #### **Product Portfolio and Innovation** - **75+ dermatologist-developed SKUs** across skin, hair, and body care, including shampoos, serums, masques, oils, and lotions. - **Nutraceuticals launched in FY25**, contributing **~5% of clinic collections**. Glutathione-based products account for **46% of the nutraceutical line**. - Strategic **collaboration with Marico Limited** to expand retail footprint: Marico handles **marketing and distribution** of Kaya products across omni-channel platforms (Nykaa, Amazon, Flipkart, Blinkit, etc.), creating a **royalty-based income stream**. - Product revenue from clinics stood at **₹2,887 lakh in FY25**, up from ₹2,746 lakh in FY24. --- #### **Geographic Presence & Expansion Strategy** - **82 clinics across India (as of Nov 2025)**, with recent launches in **Chennai, Pune, Ludhiana**, expanding to five clinics each in major metros. - New clinic openings in **high-potential Tier 2 and Tier 3 cities** to capture underserved markets. - All new and upgraded clinics feature **modern luxury designs**, **"body boutiques"**, and **immersive treatment suites** to reinforce **premium positioning**. - **Exited Middle East market** (UAE, Oman, KSA) due to **persistent losses and geopolitical volatility**, allowing capital reallocation to India. --- #### **Technology and Digital Transformation** Kaya is a pioneer in leveraging technology to enhance clinical outcomes and customer experience: - **Klear AI:** Proprietary AI-powered app trained on **thousands of Indian skin images** for faster, accurate diagnostics (ageing, acne, scars, pigmentation). Used for self-assessment and dermatologist support. - **Kaya Doctor AI App:** Enables **predictive outcome modeling, personalized treatment planning**, and enhances consultation efficiency. - **Omnichannel Platform:** - D2C site **shop.kaya.in** with AI-driven recommendations. - Clinic-facilitated fulfillment for same-day delivery. - Integration with e-commerce (Amazon, Nykaa, Blinkit, Myntra). - **Marketing Automation:** - **24/7 WhatsApp and web chatbots** for appointment booking, reminders, and queries. - Automated nudges and CRM systems boosted **conversion, retention, and customer satisfaction**. - **Internal Systems:** Powered by **Microsoft Dynamics 365 and Power BI** for data-driven decision-making and operational efficiency. --- #### **Marketing & Customer Engagement** - **Kaya Smiles Loyalty Program:** Drives **over 90% of Indian clinic collections**, with **tiered benefits** and **experiential rewards**. Evolving from transactional to **relationship-led engagement**. - **Digital-First Strategy:** - Leverages **influencer marketing, educational content, skinfluencer dermatologists**, and **Gen Z-focused campaigns**. - Focus on **outcome-based storytelling** and social media engagement (Instagram, Facebook, YouTube). - **7% of revenue** allocated to marketing, emphasizing **digital, hyperlocal activations, and brand storytelling**. - **AI and automation** contributed to incremental revenue, especially in **Acne and Brightening segments** (up to **26% increase**). --- #### **Market Position & Competitive Landscape** **Strengths:** - Market leader in **LHR, anti-ageing, and pigmentation**. - Nation’s **largest chain** of dermatologist-led aesthetic clinics. - Strong **brand trust, scientific rigor, and medical integrity**. - Early mover in **AI-enabled dermatology** and **digital diagnostics**. **Challenges:** - **High fixed costs** from physical clinic infrastructure. - **Intense competition** from digital-first D2C brands and freelance dermatologists. - **Scalability limitations** in a teledermatology-growing market. - **Talent scarcity** in qualified dermatologists. **Competitive Threats:** - **At-home laser devices**, virtual consultations, and subscription-based models. - Private equity-backed skincare startups with aggressive digital go-to-market. --- #### **Strategic Priorities (FY26 and Beyond)** 1. **Accelerate India-Focused Growth:** Expand clinic network into **Tier 2/3 cities**. 2. **Enhance Body & Hair Verticals:** Position Kaya as a **360° skin, hair, and body leader**. 3. **Deepen Digital Integration:** Scale **AI tools**, upgrade D2C capabilities, and strengthen **data-led operations**. 4. **Optimize Clinics:** Renovate, relocate underperforming units, and deploy **next-generation tech**. 5. **Return to Profitability:** Achieve **operating leverage** through **scale, technology, and efficient operations**. --- #### **Financial Highlights** - **FY24 Collections:** INR **250.2 crore** (up 7% YoY from ₹234.6 crore). - **Product Contribution:** 14% of total clinic collections. - **LHR Services:** Account for **~29.9% of Indian clinic revenue**. - **Body Contouring Segment:** Growing at **77% YoY (Q4 FY23)**.